{
    "clinical_study": {
        "@rank": "56962", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, observational study will evaluate the efficacy and safety of Tarceva\n      (erlotinib) in patients with locally advanced or metastatic adenocarcinoma non-small cell\n      lung cancer and an ECOG performance status of 0-1. Eligible patients receiving Tarceva\n      according to the Summary of Product Characteristics and local label will be followed for the\n      duration of their treatment."
        }, 
        "brief_title": "An Observational Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Histologically or cytologically confirmed, locally advanced (Stage IIIb) or\n             metastatic (Stage IV) adenocarcinoma non-small cell lung cancer\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Adequate hematologic, renal and liver function\n\n          -  Patient initiating treatment with Tarceva according to the Summary of Product\n             Characteristics\n\n        Exclusion Criteria:\n\n          -  Any contraindications to treatment with Tarceva according to the Summary of Product\n             Characteristics and local label\n\n          -  Any other malignancies within the previous 5 years, except for in situ carcinoma of\n             the cervix and basal and squamous cell carcinoma of the skin\n\n          -  Previous systemic anti-cancer treatment with HER1/EGFR inhibitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with locally advanced or metastatic adenocarcinoma non-small cell lung cancer,\n        with ECOG performance status of 0-1"
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836133", 
            "org_study_id": "ML28282"
        }, 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knez Selo", 
                        "country": "Serbia", 
                        "zip": "18000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sremska Kamenica", 
                        "country": "Serbia", 
                        "zip": "21204"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Serbia"
        }, 
        "number_of_groups": "1", 
        "official_title": "Efficacy and Safety of erLotinib (Tarceva\u00ae ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28282 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Serbia: Agency for Medicines and  Medical Devices of Serbia"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836133"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events (including SAEs and AEs of special interest)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}